Axi-cel
Axi-cel 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为B Cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
12 项
全球在招研究
2 项
已进入 III/IV 期
2 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- M.D. Anderson Cancer Center
- Lyell Immunopharma, Inc.
- H. Lee Moffitt Cancer Center and Research Institute
- Washington University School of Medicine
- Zhengzhou University
- City of Hope Medical Center
- Weill Medical College of Cornell University
- University of Michigan Rogel Cancer Center
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国
正在招募患者的 Axi-cel 研究
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
III 期招募中美国NCT07188558Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
II 期招募中美国NCT05757219NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
I 期招募中美国NCT07052305Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
IV 期招募中中国NCT06609304Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
II 期招募中美国NCT06104592Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
II 期招募中美国NCT07042438Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
I 期招募中美国NCT07725406A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
II 期招募中美国NCT06213311Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
II 期招募中美国NCT07892027Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
I 期 / II 期招募中中国NCT06902012Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
I 期招募中美国NCT05794958Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
II 期招募中美国NCT07763210
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。